LENZ Therapeutics Launches “Make it VIZZable” Consumer Campaign
On January 14, 2026, LENZ Therapeutics, Inc. (Nasdaq: LENZ) announced the debut of the “Make it VIZZable” campaign, featuring renowned actress and entrepreneur Sarah Jessica Parker (SJP) as the brand ambassador for VIZZ™ (aceclidine ophthalmic solution) 1.44%. This campaign aims to promote VIZZ, a revolutionary once-daily eye drop designed to restore near vision for up to 10 hours, providing an effective alternative to traditional reading glasses.
About the VIZZ Campaign
The “Make it VIZZable” campaign emphasizes SJP’s personal journey with age-related blurry near vision—the common condition affecting millions. Using VIZZ has transformed her experience, allowing her to enjoy daily activities without the constant ease of reach for reading glasses. SJP expressed, “It’s so nice not having to reach for my reading glasses all the time; life just becomes more efficient." She highlights how VIZZ has made everyday moments, like checking her phone and reading scripts, more convenient.
The Impact of Presbyopia
Presbyopia, an inevitable loss of near vision as one ages, affects nearly 128 million Americans and can significantly hinder daily tasks. As SJP shared, her struggle with blurry vision grew over the years, from difficulties reading at night to ultimately feeling frustrated with the reliance on glasses. “Sarah Jessica’s experience with age-related blurry near vision is so universal... We are honored to partner with SJP,” said Eef Schimmelpennink, CEO of LENZ Therapeutics.
Details on VIZZ
VIZZ, containing aceclidine, is aimed at improving near vision without causing myopic shifts. Clinical data from the CLARITY Phase 3 trial indicated that 93% of participants achieved 20/40 or better near vision within 30 minutes, lasting up to 10 hours. These results suggest that VIZZ can play a significant role for those needing assistance with reading fine print without glasses.
- VIZZ is a once-daily eye drop.
- Developed to restore near vision for up to 10 hours.
- Preservative-free, provided in single-dose vials.
- Achieves a sub-2mm pupil effect to enhance depth of field.
Safety and Usage Information
VIZZ is intended for adults with age-related blurry near vision (presbyopia). Important safety information includes:
- Do not use VIZZ if allergic to any ingredients.
- Contact lenses should be removed before application.
- Temporary dim or dark vision may occur post-application.
- Seek medical attention for sudden visual changes.
About LENZ Therapeutics
Based in San Diego, California, LENZ Therapeutics focuses on the commercialization of VIZZ, the first FDA-approved aceclidine-based treatment for presbyopia—a condition affecting approximately 1.8 billion people globally. For more details on VIZZ and the full prescribing information, please visit www.VIZZ.com.